Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Federico II University
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of classical Hodgkin lymphoma (HL)
Female sex
Age ≥18 years at the time of diagnosis
Treatment with ≥1 cycle of MBVD chemotherapy regimen
ECOG Performance Status (PS) 0-3
HIV negative status
Signed informed consent to participate in the study and for data analysis
You may not be if
Incomplete or inadequate breast cancer surveillance work-up (i.e., lacking appropriate breast imaging such as ultrasound, mammography, MRI, or cytologic/histologic assessment if clinically indicated)
Last HL-related therapy (of any line) received within 5 years from the last hematological follow-up visit
Clareo Health | Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.
